Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115948 | 0.90 | DPP4 (0.49) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL4123185 | 0.83 | DPP4 (0.35) | DPP4DPP8DPP9 | |
| SCHEMBL4114016 | 0.81 | DPP4 (0.50) | CA12CA1CA2CA9DPP4 | |
| SCHEMBL4121713 | 0.79 | ALDH1A1 (0.38) | DPP4DPP7SMN1; SMN2DPP8DPP9 | |
| SCHEMBL4125720 | 0.79 | DPP7 (0.41) | DPP4DPP7SMN1; SMN2MAPT | |
| SCHEMBL4546662 | 0.78 | DPP4 (0.49) | CA12CA1CA2CA9DPP4 | |
| SCHEMBL22991199 | 0.78 | DPP4 (0.49) | CA12CA1CA2CA9DPP4 | |
| SCHEMBL22991197 | 0.78 | DPP4 (0.49) | CA12CA1CA2CA9DPP4 | |
| SCHEMBL4128646 | 0.77 | DPP7 (0.43) | CA2DPP4DPP7SMN1; SMN2MAPT | |
| SCHEMBL4125713 | 0.77 | DPP4 (0.49) | DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | CA12 2221/4885CA1 2038/4885CA2 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.